The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics

Multiple Sclerosis and Related Disorders

Volumn 1, Issue 2, 2012, Pages 81-86

  Lindsey, J W ^a   Scott, T F ^b   Lynch, S G ^c   Cofield, S S ^d   Nelson, F ^a   Conwit, R ^e   Gustafson, T ^f   Cutter, G R ^d   Wolinsky, J S ^a   Lublin, F D ^f  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trial; Combination therapy; Glatiramer acetate; Interferon beta 1a; Multiple sclerosis; Randomized

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; PLACEBO;

ADULT; AGE; CAUCASIAN; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; EXPANDED DISABILITY STATUS SCALE; FAMILY HISTORY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; METHODOLOGY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVIEW; SAMPLE SIZE; SEX RATIO; TREATMENT OUTCOME;

EID: 84857714278     PISSN: 22110348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.msard.2012.01.006     Document Type: Article

References (25)

1. S.A. Brod, and J.W. Lindsey Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitis Annals of Neurology 47 2000 127 131 (Pubitemid 30033662)
2. J.A. Cohen, and P.A. Calabresi Avonex combination trial in relapsingremitting MS: rationale, design and baseline data Multiple Sclerosis 14 2008 370 382 (Pubitemid 351676432)
3. J.A. Cohen, and G.R. Cutter Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial Archives of Neurology 58 2001 961 967 (Pubitemid 32537471)
4. G. Comi, and V. Martinelli Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial Lancet 374 2009 1503 1511
5. A. Compston, and A. Coles Multiple sclerosis Lancet 372 2008 1502 1517
6. G.R. Cutter, and M.L. Baier Development of a multiple sclerosis functional composite as a clinical trial outcome measure Brain 122 Pt. 5 1999 871 882 (Pubitemid 29219261)
7. S. Dhib-Jalbut, and M. Chen Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis Multiple Sclerosis 8 2002 485 491 (Pubitemid 35396397)
8. C. Ford, and A.D. Goodman Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate Multiple Sclerosis 16 2010 342 350
9. L.D. Jacobs, and D.L. Cookfair Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis Annals of Neurology 39 1996 285 294 (Pubitemid 26100751)
10. K.P. Johnson, and B.R. Brooks Copolymer 1 reduces relapse rate and improves disability in relapsingremitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial Neurology 45 1995 1268 1276
11. L. Kappos, and C.H. Polman Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurology 67 2006 1242 1249 (Pubitemid 44563835)
12. F. Lublin, and M. Baier Results of the extension of a trial to assess the longer term safety of combining interferon beta-1a and glatiramer acetate Neurology 58 Suppl. 3 2002 A85
13. W.I. McDonald, and A. Compston Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis Annals of Neurology 50 2001 121 127
14. D.D. Mikol, and F. Barkhof Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial Lancet Neurology 2008
15. R. Milo, and H. Panitch Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein Journal of Neuroimmunology 61 1995 185 193
16. J.H. Noseworthy, and C. Lucchinetti Multiple sclerosis The New England Journal of Medicine 343 2000 938 952
17. P. OConnor, and M. Filippi 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsingremitting multiple sclerosis: a prospective, randomised, multicentre study Lancet Neurology 8 2009 889 897
18. C. OGorman, and S. Freeman Familial recurrence risks for multiple sclerosis in Australia Journal of Neurology, Neurosurgery and Psychiatry 82 2011 1351 1354
19. C.H. Polman, and S.C. Reingold Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria Annals of Neurology 58 2005 840 846 (Pubitemid 41746873)
20. A.H. Poonawalla, and S. Datta Composite MRI scores improve correlation with EDSS in multiple sclerosis Multiple Sclerosis 16 2010 1117 1125
21. C.M. Poser, and D.W. Paty New diagnostic criteria for multiple sclerosis: guidelines for research protocols Annals of Neurology 13 1983 227 231 (Pubitemid 13158528)
22. N.P. Robertson, and M. Fraser Age-adjusted recurrence risks for relatives of patients with multiple sclerosis Brain 119 Pt. 2 1996 449 455 (Pubitemid 26149360)
23. A.D. Sadovnick, and P.A. Baird Multiple sclerosis: updated risks for relatives American Journal of Medical Genetics 29 1988 533 541
24. M.J. Tullman, and F.D. Lublin Combination therapy in multiple sclerosis Current Neurology and Neuroscience Reports 5 2005 245 248 (Pubitemid 40873041)
25. J.S. Wolinsky, and P.A. Narayana Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators Neurology 54 2000 1734 1741